How to Get Vyleesi (Bremelanotide) in South Dakota

What Is Vyleesi and Who Is It For?

Vyleesi is a melanocortin-4 receptor agonist that the FDA approved in June 2019 for the treatment of acquired, generalized HSDD in premenopausal women. Unlike daily oral therapies such as flibanserin, bremelanotide is used on demand. Patients self-administer a 1.75 mg subcutaneous injection into the abdomen or thigh approximately 45 minutes before anticipated sexual activity.

The approval rested on the RECONNECT trial program, two replicate phase 3 studies enrolling 1,247 premenopausal women with HSDD. Across both studies, bremelanotide produced a statistically significant increase in the number of satisfying sexual events (SSEs) compared to placebo (mean increase of 1.0 SSE per month vs. 0.4, P<0.001) and reduced HSDD-related distress scores on the Female Sexual Distress Scale (FSDS-R) by a mean of 10.4 points versus 7.6 for placebo [1]. Nausea was the most common adverse event, occurring in approximately 40% of patients during the first dose but declining with subsequent use.

Vyleesi is not indicated for men, postmenopausal women, or HSDD caused by a medical condition, psychiatric disorder, or relationship factors. The FDA label explicitly excludes patients with uncontrolled hypertension or known cardiovascular disease due to transient blood pressure increases observed in clinical trials [2].

South Dakota Telehealth Prescribing Rules for Vyleesi

South Dakota law authorizes licensed prescribers to issue prescriptions via telehealth, and this authority extends to Schedule-unscheduled medications like bremelanotide. No in-person visit is required before a telehealth prescription, though the prescriber must establish a valid provider-patient relationship through a real-time audio-video encounter.

Several national telehealth platforms and sexual health clinics now serve South Dakota patients seeking HSDD treatment. A typical workflow looks like this: the patient completes a medical intake questionnaire, uploads recent lab work or medical records, then meets with a provider over video. If the clinician confirms an HSDD diagnosis using standardized screening tools (the FSDS-R Item 13 cutoff of ≥15 is commonly applied), they write the prescription electronically and transmit it to a pharmacy licensed to dispense in South Dakota.

South Dakota does not impose any HSDD-specific prescribing restrictions beyond the standard requirement for a bona fide provider-patient relationship. Both in-state and out-of-state providers may prescribe, provided they hold an active South Dakota Board of Medical and Osteopathic Examiners license or a valid interstate medical licensure compact credential. The state joined the Interstate Medical Licensure Compact, which can broaden the pool of available prescribers [3].

Who Can Prescribe Vyleesi in South Dakota?

MDs, DOs, nurse practitioners, and physician assistants with prescriptive authority in South Dakota can all write a Vyleesi prescription. South Dakota grants NPs full practice authority after a supervised transition period, meaning experienced NPs can prescribe independently without physician oversight.

For PAs, South Dakota requires a collaborative agreement with a supervising physician. The agreement must be on file, but the supervising physician does not need to co-sign each prescription. In practice, many women's health NPs and PAs in rural South Dakota communities already manage conditions like polycystic ovary syndrome and menopause. Adding HSDD screening to these visits is a natural extension of their scope.

Specialists who commonly prescribe bremelanotide include OB/GYNs, sexual medicine physicians, and endocrinologists. Primary care physicians can also prescribe Vyleesi once they have confirmed the HSDD diagnosis and ruled out other causes of low desire, including thyroid dysfunction, depression, and medication side effects (SSRIs and hormonal contraceptives are frequent contributors) [4].

What Labs and Workup Are Needed Before Prescribing?

The FDA label for Vyleesi does not mandate specific laboratory testing prior to prescribing. Clinical best practice, however, calls for a focused workup to exclude secondary causes of low sexual desire and to confirm patient safety.

A standard pre-prescription workup includes:

• Thyroid panel (TSH, free T4): Hypothyroidism and hyperthyroidism both suppress libido. Correcting an abnormal TSH may resolve HSDD symptoms without additional medication [5].
• Complete metabolic panel (CMP): Establishes baseline renal and hepatic function. Bremelanotide is hepatically metabolized, so significant liver impairment warrants caution.
• Prolactin level: Hyperprolactinemia, sometimes drug-induced, is a recognized cause of decreased sexual desire in premenopausal women.
• Blood pressure measurement: The Vyleesi label warns of transient increases in systolic blood pressure (mean increase of 6 mmHg) and decreases in heart rate following injection. Patients with uncontrolled hypertension (systolic ≥160 or diastolic ≥100) should not use bremelanotide [2].
• Depression screening (PHQ-9): HSDD frequently co-occurs with depressive disorders. Distinguishing primary HSDD from desire loss secondary to depression changes the treatment plan.

Most telehealth providers accept labs drawn within the prior 6 to 12 months. If a patient does not have recent labs, telehealth platforms typically order them through a national lab network (Quest, Labcorp) with draw sites in Sioux Falls, Rapid City, Aberdeen, and other South Dakota cities.

Pharmacy Access and 503A Compounding in South Dakota

South Dakota patients have two main pharmacy pathways for obtaining bremelanotide: the brand-name Vyleesi autoinjector dispensed through retail or specialty pharmacies, and compounded bremelanotide from a licensed 503A compounding pharmacy.

Brand-name Vyleesi is available at most specialty pharmacies that ship nationwide. Because Vyleesi is not stocked at every retail location, many patients use mail-order specialty pharmacy services. A prescription transmitted electronically from a telehealth visit typically ships within 3 to 5 business days to a South Dakota address. Patients in more remote areas of western South Dakota should expect delivery at the longer end of that window.

503A compounding pharmacies in South Dakota are licensed by the South Dakota Board of Pharmacy and may compound bremelanotide from bulk pharmaceutical-grade powder when a patient-specific prescription exists. Compounded bremelanotide is dispensed as a subcutaneous injectable solution in multi-dose vials rather than pre-filled autoinjectors. The cost difference can be substantial. Brand-name Vyleesi carries a list price near $950 per autoinjector (each containing a single dose), while compounded bremelanotide may cost $50 to $150 per multi-dose vial containing 5 to 10 doses, depending on the pharmacy and concentration.

A 503A pharmacy must compound pursuant to a valid, patient-specific prescription. It cannot advertise or distribute compounded bremelanotide in bulk without individual orders. Patients should confirm that any compounding pharmacy they use is licensed in South Dakota and complies with USP 797 sterile compounding standards [6].

Insurance Coverage and Prior Authorization in South Dakota

Coverage for Vyleesi varies significantly by payer. South Dakota Medicaid does not cover bremelanotide for HSDD. Most commercial insurers classify it as a specialty-tier drug and require prior authorization before approving coverage.

Prior authorization documentation in South Dakota typically requires:

1. Confirmed HSDD diagnosis using ICD-10 code F52.0, with documentation that the condition is acquired and generalized (not situational or lifelong).
2. Trial and failure of non-pharmacologic interventions, such as cognitive behavioral therapy or sex therapy, though some insurers waive this requirement.
3. Trial and failure or contraindication to flibanserin (Addyi), the only other FDA-approved HSDD medication in premenopausal women. Many plans use a step-therapy protocol requiring flibanserin first.
4. Prescriber attestation that the patient is premenopausal, not pregnant, and has no uncontrolled hypertension.

The turnaround time for prior authorization decisions ranges from 48 hours to 14 business days depending on the insurer. South Dakota state law requires commercial health plans to respond to prior authorization requests within 2 business days for non-urgent requests [7].

For patients whose insurance denies coverage, alternatives include the Vyleesi copay savings program (eligible commercially insured patients may pay as little as $0 per prescription for a limited period), patient assistance programs through the manufacturer, or switching to compounded bremelanotide, which is almost always a cash-pay transaction not submitted to insurance.

Transferring a Vyleesi Prescription to South Dakota

Patients relocating to South Dakota or visiting from another state can transfer an existing Vyleesi prescription. South Dakota Board of Pharmacy rules permit prescription transfers between licensed pharmacies. The receiving pharmacy contacts the originating pharmacy to verify the prescription details, remaining refills, and prescriber information.

For telehealth patients, the process is even simpler. If the prescribing provider is licensed in both the originating state and South Dakota (or holds an Interstate Medical Licensure Compact license), they can issue a new prescription directly to a South Dakota pharmacy without a formal transfer. Patients should allow 5 to 7 days for the new pharmacy to process the prescription, verify insurance or payment, and ship the medication.

One consideration: compounded bremelanotide prescriptions may not transfer as easily, because compounding formulations differ between pharmacies. In most cases, the new compounding pharmacy will request a fresh prescription from the provider specifying their own formulation and concentration [8].

How Long Until You Receive Vyleesi in South Dakota?

The total timeline from initial consultation to medication in hand depends on the prescribing pathway chosen.

Telehealth-to-specialty-pharmacy route: Patients who have recent labs available can often complete a telehealth consultation within 1 to 3 days of requesting an appointment. Once the prescription is written, specialty pharmacy fulfillment takes 3 to 5 business days. Total: roughly 5 to 8 business days.

Telehealth with new labs needed: Add 3 to 7 days for lab orders, specimen collection, and result delivery. Total: roughly 10 to 15 business days.

In-person visit route: Scheduling availability with an OB/GYN or sexual medicine specialist in South Dakota varies. In Sioux Falls or Rapid City, wait times for a new-patient appointment range from 2 to 6 weeks. Rural areas may have longer waits. After the appointment, pharmacy fulfillment follows the same 3-to-5-day timeline.

503A compounding pharmacy route: Compounding may add 2 to 5 business days beyond standard dispensing time, depending on whether the pharmacy compounds bremelanotide on a regular batch schedule or only upon receipt of a prescription.

Safety Monitoring and Follow-Up

After starting Vyleesi, patients should plan for a follow-up with their prescriber at 8 to 12 weeks. This visit (which can be conducted via telehealth) evaluates treatment response, side-effect tolerability, and blood pressure stability.

Nausea management is the most common clinical issue in early treatment. In the RECONNECT trials, 40% of patients reported nausea after the first dose, but this rate dropped to approximately 3% by the eighth dose [1]. Prescribers often recommend starting with a light meal 1 to 2 hours before the injection and having ondansetron 4 mg on hand for the first few uses.

Focal skin hyperpigmentation can occur with repeated use, particularly in patients with darker skin tones. The FDA label notes that 1% of clinical trial participants developed hyperpigmentation, most commonly on the face, gingiva, and breasts. This pigmentation change may not fully resolve after discontinuation [2].

Patients should not use Vyleesi more than once in a 24-hour period and should not exceed 8 doses per month. There is no clinical data supporting daily use, and the transient cardiovascular effects (blood pressure elevation, heart rate reduction) are a reason to respect dosing limits.

Cost Comparison: Brand vs. Compounded Bremelanotide in South Dakota

The cost gap between brand-name Vyleesi and compounded bremelanotide is one of the largest in the HSDD treatment category.

| Option | Approximate cost per dose | Doses per unit | Notes | |---|---|---|---| | Brand Vyleesi autoinjector | $850 to $950 | 1 | Single-use prefilled autoinjector | | Compounded bremelanotide (503A) | $10 to $30 | 5 to 10 per vial | Requires self-drawing from vial with insulin syringe | | Vyleesi with copay card | $0 to $50 | 1 | Commercial insurance required; time-limited offer |

Patients choosing the compounded route should be trained on proper subcutaneous injection technique, sterile vial handling, and appropriate needle gauge selection (typically 27- to 30-gauge, 0.5-inch needles). Many telehealth platforms include injection training videos as part of the onboarding process [9].